![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Vernon John A. Golec Joseph H.
Publisher: Adis International
ISSN: 1170-7690
Source: PharmacoEconomics, Vol.28, Iss.10, 2010-10, pp. : 877-887
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Comparative Effectiveness Research: The View from a Pharmaceutical Company
By Berger Marc L. Grainger David
PharmacoEconomics, Vol. 28, Iss. 10, 2010-10 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Comparative Effectiveness, Personalized Medicine and Innovation: The Path Forward
PharmacoEconomics, Vol. 28, Iss. 10, 2010-10 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
The cost of pharmaceutical innovation to patients
By Keyhani Salomeh Ross Joseph S
Expert Opinion on Drug Discovery, Vol. 2, Iss. 11, 2007-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
The price to pay for pharmaceutical innovation
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 431, 2003-01 ,pp. :